HLF - HLF transcription factor, PAR bZIP family member Gene

Species: Homo sapiens

Gene Type: protein coding
Gene ID: 3131

About HLF

Cytogenetic location: 17q22 Genomic coordinates (GRCh38): 17:55,264,960-55,325,187 (from NCBI)

This gene has 11 transcripts (splice variants), 262 orthologues, 2 paralogues and is associated with 62 phenotypes. Broad expression in liver (RPKM 22.6), brain (RPKM 22.4) and 18 other tissues.

Summary

This gene encodes a member of the proline and acidic-rich (PAR) protein family, a subset of the bZIP transcription factors. The encoded protein forms homodimers or heterodimers with Other PAR family members and binds sequence-specific promoter elements to activate transcription. Chromosomal translocations fusing portions of this gene with the E2A gene cause a subset of childhood B-lineage acute lymphoid leukemias. Alternatively spliced transcript variants have been described, but their biological validity has not been determined. [provided by RefSeq, Jul 2008]

HLF Products (2)

mRNA Protein Name
NM_001330375.2 NP_001317304.1 hepatic leukemia factor isoform 2
NM_002126.5 NP_002117.1 hepatic leukemia factor isoform 1

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables DNA-binding transcription activator activity, RNA polymerase II-specific IDA
IDA: Inferred from direct assay
8065331 GOA
enables DNA-binding transcription activator activity, RNA polymerase II-specific IMP
IMP: Inferred from mutant phenotype
8065331 GOA
enables protein binding IPI
IPI: Inferred from physical interaction
20102225 GOA
enables sequence-specific DNA binding IMP
IMP: Inferred from mutant phenotype
8065331 GOA
enables sequence-specific double-stranded DNA binding IDA
IDA: Inferred from direct assay
28473536 GOA
Biological Process GO Annotation Evidence References Source
involved in positive regulation of transcription by RNA polymerase II IDA
IDA: Inferred from direct assay
8065331 GOA
Cellular Component GO Annotation Evidence References Source
part of RNA polymerase II transcription regulator complex IPI
IPI: Inferred from physical interaction
23661758 GOA
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

HLF Protein Structure

bZIP_2

bZIP_2: Basic region leucine zipper (224 - 277)

  • 0
  • 100
  • 200
  • 295 a.a.
Protein Preferred Names Protein Names

hepatic leukemia factor

  • E2A-HLF fusion transcript protein

HLF Protein-protein interaction Information

Type
Protein Name Protein ID Interactor Interactor Species Interactor ID Detection Method References
Intra
HLF Q16534 BATF3 Homo sapiens Q9NR55
Peptide Array
20102225
Intra
HLF Q16534 BATF3 Homo sapiens Q9NR55
FRET
23661758
Intra
HLF Q16534 DBP Homo sapiens Q10586
FRET
23661758
Intra
HLF Q16534 DBP Homo sapiens Q10586
Y2H
21988832
Intra
HLF Q16534 DDIT3 Homo sapiens P35638
Peptide Array
20102225
Intra
HLF Q16534 DDIT3 Homo sapiens P35638
FRET
23661758
Intra
HLF Q16534 BATF Homo sapiens Q16520
FRET
23661758
Intra
HLF Q16534 BATF Homo sapiens Q16520
Peptide Array
20102225
Cross: Cross-species interaction Intra: Intraspecies interaction

HLF Antibodies

Cat. No. Product Name Application Reactivity
HY-P83245 HLF Antibody (YA2990) WB Human
HY-P83245A HLF Antibody (YA2990)(PBS only) WB Human

Related Diseases

Diseases Alias
B-Lymphoblastic Leukemia/Lymphoma With Recurrent Genetic Abnormality
Leukemia

  • Leukemias

  • Leukaemia, Unspecified, Without Mention Of Remission

  • Aleukemic Leukaemia

  • Chronic Leukaemia

  • Subacute Leukaemia

  • Leukaemia Disorder

  • Leukaemia Nos
Partial Motor Epilepsy

  • Epilepsy, Partial, Motor

  • Epilepsy, Focal Motor

  • Focal Motor Seizure
Leukemia, Acute Lymphoblastic

  • Acute Lymphoblastic Leukemia

  • ALL

  • Acute Lymphocytic Leukemia

  • Leukemia, Acute Lymphocytic, Susceptibility To, 1

  • Acute Lymphoblastic Leukaemia

  • Precursor Lymphoblastic Lymphoma/Leukemia

  • Precursor Lymphoid Neoplasm

  • Leukemia, Acute Lymphoblastic, Susceptibility To

  • B-Cell Acute Lymphoblastic Leukemia

  • Leukemia, Acute Lymphocytic 1

  • Acute Lymphocytic Leukaemia

  • Acute Lymphoblastic Leukemia/Lymphoma

  • All1

  • Childhood Acute Lymphoblastic Leukemia

  • Leukemia Acute Lymphoblastic 1

  • Leukemia Acute Lymphoblastic B-Hyperdiploid

  • Leukemia Acute Lymphocytic

  • Leukemia Acute Lymphocytic 1

  • Leukemia B-Cell Acute Lymphoblastic

  • Leukemia T-Cell Acute Lymphoblastic

  • Leukemia, Acute Lymphoblastic, 3

  • ALL3

  • Lymphoblastic Leukemia Acute

  • Leukemia, Acute, Lymphoblastic

  • Precursor Cell Lymphoblastic Leukemia Lymphoma

  • Leukemia, Lymphocytic, Acute, L1

  • Leukemia, Acute Lymphoblastic, Susceptibility To, 3
Erythrocytosis, Familial, 1

  • ECYT1

  • Pfcp

  • Primary Familial And Congenital Polycythemia

  • Familial Erythrocytosis 1

  • Familial Erythrocytosis

  • Polycythemia, Primary Familial And Congenital

  • Autosomal Dominant Benign Erythrocytosis

  • Familial Erythrocytosis Type 1

  • Congenital Erythrocytosis Due To Erythropoietin Receptor Mutation

  • Congenital Polycythemia Due To Erythropoietin Receptor Mutation

  • Primary Congenital Erythrocytosis

  • Primary Familial Polycythemia

  • Erythrocytosis, Autosomal Dominant Benign

  • Erythrocytosis, Somatic

  • Autosomal Dominant Familial Erythrocytosis-1

  • Erythrocytosis Autosomal Dominant Benign

  • Familial Primary Polycythemia

  • Familial Erythrocytosis, 1

  • Erythrocytosis, Familial, Type 1
Diseases Alias
Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Related Agents

  • Clinical Phase
  • Pre-clinical Phase

Clinical Phase

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Phase
HY-106228 HLF1-11 Inhibitor 99.73% Phase 2

Pre-clinical Phase

Bioactive Molecules (11)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-RS04409 EPAS1 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-144075 JAK-IN-19 Inhibitor / Unkown
HY-146724 Dot1L-IN-7 Inhibitor / Unkown
HY-147946 PDE1-IN-4 Inhibitor / Unkown
HY-P11131 hLF (28-34) Inhibitor / Unkown
HY-RS06219 HLF Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-172462 Mtb-IN-11 Inhibitor / Unkown
HY-RS18116 Hlf Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS18998 Epas1 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS24590 Hlf Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS25487 Epas1 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
Inhibitory Antibodies (1)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P990867 Anti-CD220/Insulin Receptor Antibody (IR 83-22) Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Mus musculus HLF MGD MGI:96108
Bos taurus HLF VGNC VGNC:50275
Rattus norvegicus HLF RGD RGD:1582828
Macaca mulatta HLF VGNC VGNC:73478
Canis familiaris HLF VGNC VGNC:49094
Felis catus HLF VGNC VGNC:67589
Others HLF NCBI